Sun Pharma Q4 Review: Brokerages Stay Bullish Despite Soft FY26 Guidance
Sun Pharmaceutical Industries Ltd. posted a mixed fourth quarter on Thursday and announced a softer-than-expected financial year 2026 guidance. However, Citi and Macquarie maintained positive outlooks, citing long-term growth potential and ongoing investments in specialty products.
The fourth quarter results were modestly below estimates. Macquarie reported a 1% revenue miss and 6% Ebitda miss, while Citi noted that strength in India and emerging markets helped offset weakness in US generics. Specialty revenues grew 9% year-on-year to $295 million, while India sales rose 14% year-on-year. Ebitda margin improved by 60 basis points year-on-year to 26.4%, despite limited contribution from generic Revlimid.
Citi has raised its target price to Rs 2,210 from Rs 2,080, rolling forward to March 2027 earnings. Macquarie maintained its Rs 2,135 target, noting upside potential despite a modest operating miss. Both firms reduced financial year 2026 EPS estimates due to launch costs and higher tax rates but left fiscal 2027 estimates unchanged.
Management guided for mid- to high-single-digit revenue growth for financial year 2026, below the 11% expected by consensus of Macquarie. Citi attributes the conservative outlook to regulatory and geopolitical uncertainty rather than core business issues. The brokerage expects 9% revenue growth in fiscal 2026, supported by India and emerging markets, new launches in specialty, and a bottoming out of generics.
The drug maker has planned $100 million in financial year 2026 spending related to US launches of Leqselvi and Unloxcyt. While this weighs on near-term margins, both brokerages believe the investment is non-recurring and sets the stage for fiscal 2027 margin expansion. Citi models flat fiscal 2026 Ebitda margins, followed by a 200-basis points improvement in the next fiscal as launch expenses taper and new products gain traction.
The success of Leqselvi and Unloxcyt will be key, said Citi. Both products have strong clinical profiles but face entrenched competition from Pfizer and Regeneron. Sun Pharma's willingness to spend aggressively signals a firm commitment to building its specialty franchise.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
